Is COX-2 a 'collateral' target in cancer prevention?

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Non-steroidal anti-inflammatory drugs (NSAIDs) are known to prevent various cancers, including colon cancer.
• The mechanism involves inhibition of the eicosanoid pathway, with a focus on cyclo-oxygenase (COX) enzymes.
• Overexpression of COX-2 and increased prostaglandin E2 levels in cancers supported clinical trials for COX-2 inhibitors in cancer prevention.

Purpose of the Study:

• To evaluate the efficacy of COX-2 inhibitors for cancer prevention.
• To investigate the role of COX-2 as a target for cancer prevention.
• To explore alternative targets beyond COX-2 for cancer prevention strategies.

Main Methods:

• Review of existing evidence on NSAIDs and COX-2 inhibitors in cancer prevention.
• Analysis of COX-2 expression in pre-malignant and malignant colon tissues.
• In vitro studies assessing NSAID efficacy independent of COX-2.
• Clinical data analysis from studies involving COX-2 inhibitors and NSAIDs in conditions like familial adenomatous polyposis.

Main Results:

• COX-2 is not consistently expressed in early pre-malignant lesions (aberrant crypt foci) or in a majority of adenomas.
• In vitro data indicate that NSAIDs can prevent cancer independent of COX-2.
• COX-2 inhibitors have shown modest effects, sometimes weaker than traditional NSAIDs, and possess COX-2-independent activities.

Conclusions:

• COX-2 may not be the sole or optimal target for cancer prevention.
• Limitations and cardiovascular side effects associated with COX-2 inhibitors warrant caution.
• The need to explore multiple COX-2-independent targets for developing effective cancer prevention strategies is highlighted.